TrialBlood2023

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.

Stéphane de Botton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.